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Abstract
Background: Randomised controlled trials are considered the best method for determining the effectiveness and
safety of health interventions. Trials involving children are essential to ensure that treatments are safe and effective.
However, many trials, in both adult and paediatric populations, do not achieve recruitment targets and/or maintain
retention of participants, which can lead to a reduction in the internal and external validity of the results.
Identifying ways of improving trial efficiency are important in order to increase the successful completion of trials.
Main body: A ‘Study Within A Trial’ (SWAT) is a self-contained study embedded within an ongoing trial, which aims
to establish evidence to improve the management and delivery of trials in healthcare. Increasing numbers of
SWATs have been undertaken in recent years yet very few within paediatric trials. Herein, we describe some of the
challenges with undertaking a programme of SWATs within paediatric clinical trials in the UK. The TRECA (TRials
Engagement in Children and Adolescents) study involves developing multimedia websites for use within paediatric
trials to provide recruitment information to children, young people and their families about the clinical trial.
Challenges encountered included governance issues such as host trial approval processes and sharing of
anonymised data, funding issues for host trials, internet quality and accessibility within the healthcare setting, and
ethical concerns associated with SWAT methodology. We believe the ethical concerns are more pronounced in the
paediatric setting, perhaps because of the fewer SWATs undertaken in these settings or that a more cautious,
risk-averse approach to undertaking research with children is taken.
Conclusion: SWATs are becoming increasingly common to provide an evidence base for methods to improve trial
efficiency. However, we encountered a number of unanticipated challenges to embedding TRECA that have not
been previously reported within the scientific literature. We believe that, if these issues were addressed through
wider promotion and explanation of undertaking SWATs involving all key stakeholders, as well as by exploration of
alternative funding models for SWATs, this would enable more streamlined, appropriate and timely processes for
SWATs and a stronger evidence base for what works to increase trial efficiency.
Trial registration: The TRECA study is registered on ISRCTN, ID 73136092. Registered on 24 August 2016.
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Background
The need for evidence-informed trials
Although randomised controlled trials (RCTs) are the
gold standard for developing an evidence base on the
effectiveness of healthcare interventions, significant
uncertainties exist about their design, conduct and
reporting, meaning that trials are often not efficient. For
example, approximately 50% of trials fail to achieve their
original recruitment targets [1]. Poor recruitment and
retention of trial participants can be very costly [2] and
contribute significantly to research waste [3, 4].
The UK government has highlighted its ambition to
accelerate the development of innovative medicines to
improve patient health outcomes and healthcare
efficiency [5]. However, without the ability to accelerate
the evaluation of healthcare innovations, and for these
evaluations to be completed in time and to target, this
ambition will be stymied. Furthermore, despite our focus
on the UK, this issue is faced by many health systems
around the world.
‘Study Within A Trial’ (SWAT), an emerging field
With the recognition that developing the evidence base
for trials should be a priority, there has been a recent
international movement to improve the efficiency and
successful delivery of trials through the use of rigorous
evaluation, adopting the SWAT methodology. A SWAT
is a “self-contained study that has been embedded within
a host trial with the aim of evaluating or exploring
alternative ways of delivering or organising a particular
trial process” [6]. For instance, in the UK, the Medical
Research Council funded the START (Systematic Tech-
niques for Assisting Recruitment to Trials) programme,
which successfully developed a conceptual, methodo-
logical and logistical framework to improve recruitment
through embedding SWATs of recruitment interventions
in multiple host trials, and developed reporting
guidelines for recruitment SWATs [7, 8]. The Northern
Ireland Hub for Trials Methodology Research has
established the SWAT Repository to facilitate SWATs
[9]. Trial Forge is another UK initiative, based in
Scotland, that aims to increase the evidence base for trial
decision-making and, in doing so, improve trial
efficiency. Trial Forge recently published guidance for
defining a SWAT [6]. The current Medical Research
Council-funded PROMoting THE USE of SWATs (PRO-
METHEUS) programme [10] is building on the START
initiative to make SWATs standard practice in clinical
trials in the UK by funding and facilitating the initiation
of at least 25 SWATs across multiple teams in the UK.
Recently, the UK National Institute for Health Research
(NIHR) announced a new funding stream for SWATs in
the Health Technology Assessment (HTA) programme
[11], which has the potential to increase the number of
trial teams likely to consider and/or actively undertake
SWATs. In the Republic of Ireland, the Health Research
Board – Trials Methodology Research Network, sup-
ports and funds research teams to undertake SWATs to
improve the efficient conduct of future trials [12].
Previously identified challenges with SWATs
Despite the current focus on SWATs, a range of
challenges to undertaking them have been identified.
Challenges for host trials include increased complexity
and management burden, compatibility between the host
and embedded trials, and the impact of the embedded
trial on host trial design and relationships with collabo-
rators [13]. For embedded trials, there are concerns that
host trial investigators might have strong preferences,
limiting the control that embedded study investigators
have over their research, and that inadequate sample
sizes may limit statistical power [13]. Other identified
challenges include cost, resistance of the chief investiga-
tor or co-investigators, funding for SWATs, and distrac-
tion and additional workload for research staff [14, 15].
The TRECA Study, an example of a SWAT to evaluate a
new recruitment intervention
In this paper, we discuss some of the challenges encoun-
tered within a programme of SWATs, the TRials Engage-
ment in Children and Adolescents (TRECA) Study [16],
funded by the UK NIHR Health Services and Delivery
Research Programme (14/21/21). TRECA is investigating
a novel alternative to a printed participant information
sheet (PIS) for children, young people and their parents,
when approached about a clinical trial. This is an
important opportunity to explore alternative methods of
providing information as many PIS documents are
lengthy, difficult to understand and do not incorporate
visual elements [17–20]. In the first phase of the TRECA
study, multimedia website templates about paediatric
clinical trials using text, pictures, animations and short
video clips were developed [21] and user tested [22].
Phase two of TRECA began in late 2017 and involves
adapting the multimedia websites for six paediatric clin-
ical trials (host trials) using trial-specific content and
embedding the websites as recruitment tools within the
host trials. There is a lack of evidence on the effective-
ness of multimedia for supporting decision-making
about trials, particularly in the paediatric setting. When
host trials embed TRECA, the trial randomises those
approached about trial participation to one of three arms
of TRECA so that each person approached receives one
of the following: the PIS only, the multimedia website
only, or both the PIS and multimedia website. We are
interested in the impact of the multimedia websites on
the recruitment and retention rates to the six trials, as
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well as the quality of decision-making by families about
trial participation.
Despite much interest and enthusiasm for SWATs,
and clear benefits for utilising them to evaluate new
methodological interventions within RCTs [6], we have
encountered a number of challenges to embedding
TRECA within UK paediatric trials. Herein, we describe
these challenges and suggest some possible solutions
that may enable SWATs to be undertaken more quickly
and efficiently within a paediatric context, or other set-
tings where there is a perception of patient vulnerability
or risk.
Challenges faced by TRECA
The main challenges encountered when engaging with
potential host trials to embed TRECA fall under four
main categories, namely governance and approvals,
funding;, methodological/ethical concerns, and internet
access and quality.
Governance and approvals issues
A number of governance and approvals issues have been
encountered when embedding TRECA within host
paediatric trials. Within Phase two of TRECA, each of
the six host trials had different approval processes to
embed TRECA. Some trials required their Trial Manage-
ment Group (TMG) to formally approve collaboration.
Other host trials requested that a feasibility question-
naire be developed by TRECA and sent to all potential
host trial sites. The questionnaires were accompanied by
information about TRECA in terms of the practicalities
of what would be involved if the host trial site was to
embed TRECA. We sought each site’s approval and
agreement with embedding TRECA through the comple-
tion of a set of questions relating to the process of em-
bedding TRECA. From this, the decision still rested with
the TMG, which may have only met infrequently. One
host trial required two sets of feasibility questionnaires
to be circulated to the trial sites – one prior to a
decision by the host TMG about embedding TRECA,
and another following this decision. In our experience, it
often took 3–8 months from initial discussions with the
potential host trial until the trial made a decision about
embedding TRECA; this had an important time-delaying
impact on TRECA’s timelines. Crucially, TRECA could
not begin developing the multimedia websites (given
they are tailored to the trial) until the decision was made
by the host trial, and the delay then impacted on the
development and embedding of the websites (the tested
recruitment intervention).
So that TRECA could evaluate the impact of the
multimedia websites on recruitment, retention and qual-
ity of decision-making, we required anonymised patient
data from each host trial. To this end, we developed a
data sharing agreement. Whilst we expected that these
agreements would be straightforward, host trial sponsors
raised concerns about sharing even anonymised data,
and legal teams from the host trials’ sponsors reviewed
and queried the agreements prior to signing. In addition,
recent changes in data protection with the recent
General Data Protection Regulation and Data Protection
Act 2018 also led to further concerns about sharing of
anonymised data and the need for a transparent
approach to informing participants about the sharing of
their data between organisations. One host trial noted
that the sponsor of the host trial would not be signing
the agreement, and instead required each participating
host trial site to sign an individual data-sharing agree-
ment with TRECA, increasing the administration and
workload substantially.
Funding issues for trials embedding SWATs
Another challenge encountered relates to funding. The
NIHR Clinical Research Network (CRN) provides fund-
ing to trials in the UK through the process of funding
per participant recruited (accruals) for so-called ‘portfo-
lio-adopted’ research studies. The Portfolio comprises
high quality clinical research studies that are eligible for
CRN funding and support. Recruitment data allows the
allocation of funding to the NIHR Local CRNs to direct
National Health Service (NHS) support to sites. Almost
every trial we have approached about TRECA has asked
or assumed that the host trial would receive two sets of
accruals – one for recruitment of their participants into
the host trial, and the second for those who were rando-
mised to TRECA. However, the CRN considers this
situation to be ‘double-counting’ as all of those recruited
to the host trial would have been approached using one
of the arms of TRECA and an additional consent
process for the SWAT is not required. Nevertheless, we
can see the trial’s view that by embedding TRECA they
are introducing a greater workload, although the TRECA
team aims to reduce this burden as much as is practic-
able. Receiving additional funding for the local CRN
may provide an incentive for a trial to embed a SWAT,
particularly for the recruiters, as this funding may enable
the CRN to support the trial team.
Another accrual issue relates to a potential host trial
for TRECA that was not portfolio adopted. This particu-
lar host trial team thought that by embedding TRECA,
which is an NIHR portfolio-adopted study, they would
then be able to access an NIHR research nurse through
funding/accruals to undertake recruitment for the host
trial. However, this was not possible under the current
CRN process. This raises the question of whether an-
other funding model would assist with recruiting trials
to undertake SWATs. A middle ground may be to
provide a recruitment incentive for trials to undertake
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SWATs but below the level of accrual/funding for
recruiting a trial participant. Another option is to utilise
the PROMETHEUS [10] model (https://www.york.ac.uk/
healthsciences/research/trials/research/swats/prometheus/)
with a flat rate for a SWAT provided to the trial team.
Confusion around embedded trial methodology and
ethical concerns
Trialists have often been unsure about the methodology
and approvals of embedded trials. We sought overarch-
ing research ethics and Health Research Authority
(HRA) approvals for TRECA prior to identifying and
approaching potential host trials. In this overarching
ethics application, we sought (and received) approval so
that host trials do not need to explain TRECA or seek
consent for those approached about the host trial in
order to be randomised within TRECA. This is because
explaining TRECA to those approached about the host
trial and seeking consent to TRECA would be confusing
and may also confound the effect of the information
intervention being tested in the SWAT. However, trials
have generally expressed concern about people not
needing to consent to the embedded trial, despite these
concerns not being raised by research ethics committees
or the HRA.
In addition, NHS Trust Research & Development
(R&D) departments (located within NHS sites and
responsible for granting approval for research studies
being undertaken locally) are often unclear of how to
review and approve embedded trials, which causes de-
lays. For example, one trial initially reviewed the TRECA
documentation as an embedded study and then decided
that TRECA would be reviewed as a stand-alone study,
subsequently requesting all documentation to be sent
again and reviewed. In addition, R&D departments were
often unsure about which documentation they needed to
review and some had concerns about participants not
consenting to the SWAT (despite ethics approval for this
process). These additional steps caused further delays in
embedding TRECA.
Accessibility and quality of internet provision
An unexpected challenge with undertaking a SWAT
involving the delivery of a multimedia website within the
healthcare setting was the variation in Wi-Fi network
conditions and permissions at each NHS site. This
proved challenging when developing the multimedia
websites for host trials as the Principal Investigator for
one host trial was unable to view the websites due to
internet viewing restrictions at the hospital (the videos
and animations are stored on a site which was blocked
at this particular hospital). Furthermore, some Wi-Fi
networks were either too slow to load animations and
videos or could not be reliably accessed. We overcame
this issue by providing affected sites with a tablet
computer that had an internet SIM card.
Other learnings from the TRECA study
Despite the challenges we faced with incorporating this
programme of SWATs within six host trials, we encoun-
tered a number of positive experiences. There is a genu-
ine interest in presenting information about trials to
families in a more engaging way and there has been a
great deal of enthusiasm for the multimedia websites
created. We also found Research Ethics Committees and
the HRA to be very supportive of us evaluating the use
of multimedia websites as an alternative or supplement
to printed PIS documents. We also developed a
structured and quality method of creating multimedia
websites by working with host trials and a company that
specialises in developing websites and animation
(Morph; www.morph.co.uk). For researchers wanting to
implement SWATs in the future, we would recommend
early engagement with all stakeholders (including
trialists, sponsors, R&D department staff ) about incorp-
orating a SWAT so that any concerns or queries are
addressed early. We would also factor in a lead time
of 6 months for trials to sign the data-sharing agreement.
Conclusions
SWATs have become increasingly popular, offering an
opportunity to identify what works best when undertak-
ing trials [6]. In conducting Phase two of the TRECA
study, we identified and described a number of govern-
ance, funding and methodological challenges when
embedding a programme of SWATs within host paediat-
ric trials. There are a small number of publications
describing challenges with embedding SWATs [13–15];
however, some of the issues identified within the TRECA
study have not previously been described and this paper
provides detailed information about the challenges faced.
We also are not aware of any publications about SWATs
undertaken within paediatric trials, and believe that
some of the challenges we have experienced have a more
marked impact in the paediatric context and in other
contexts where there is a perception of increased patient
vulnerability or risk. For example, a recent Cochrane re-
view showed that only one of 68 trials evaluating strat-
egies to improve recruitment into RCTs had included a
paediatric sample [23]. However, we believe that the
challenges we have identified within TRECA may be ap-
plicable to trials with other populations, including trials
involving adults, and are relevant for other researchers
wishing to undertake SWATs in a variety of trials and
settings. We also acknowledge that the issue of internet
quality and access will only impact on SWATs that in-
volve delivery of websites and not on other methods of
information provision.
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We believe that the identified challenges can be
overcome, enabling a more streamlined and proportionate
approach to trials reviewing requests for SWATs. We
suggest that increasing awareness of SWATs more widely
in the UK, such as through publications and presentations,
and ensuring that paediatric trialists are involved, would
assist with some of the ethical concerns raised, including
participants not needing to provide explicit consent for the
SWAT. We feel that the ethical concerns expressed by host
trials for TRECA reflect that this study was undertaken in
the paediatric setting where there may be more caution
about novel methods. It is important that all stakeholders
are involved in a process of increasing SWAT awareness,
including members of ethical committees, sponsor repre-
sentatives, principal investigators, trial managers and coor-
dinators, TMGs, CRNs, R&D officers, trial managers, and
coordinators at trial sites and clinical trial units.
We also feel that the provision of more guidance to
NHS sites and trials about how to review a SWAT, and
earlier identification of whether the host trial is able to
embed it, would be beneficial. Undertaking feasibility
assessments with sites participating in a multi-centre
trial takes considerable time in order to develop and
distribute the questionnaire, answer site queries, collate
results and then await TMG review. In addition, we have
found that a number of R&D departments are not famil-
iar with SWAT methods, how to review SWATs, or the
order in which they should review and approve studies
(i.e. approval before or after the host trial). R&D depart-
ments ultimately approve the undertaking of SWATs at
sites and are often not involved in early discussions with
trialists about including a SWAT. Ensuring that R&D
departments are more familiar with SWATs would
streamline the process of incorporation within new and
existing trials. If these elements can be addressed, we
would hope that this would enable more SWATs to be
undertaken, providing a stronger evidence base about
what works best in RCTs. In terms of funding models
for host trials embedding a SWAT, we feel that alterna-
tive models should be explored to generate incentives
for host trials that match the workload of undertaking
the SWAT, and the HTA funding stream may provide a
viable funding alternative. We have described the UK
situation but feel that these issues of funding support to
host trials may be similar in other countries.
In summary, we suggest that the following actions
may overcome some of the challenges with undertaking
SWATs in the paediatric setting:
1. Reduce ethical approval and governance barriers by
increasing awareness of SWATs and engaging all
stakeholders (including ethical committees, sponsor
representatives, principal investigators, trial managers
and coordinators, TMGs, R&D and trial sites).
2. Provide more guidance and explanation about
SWATs. In the UK, this could be led by NIHR or
HRA, who are perhaps best positioned to provide
the guidance and support.
3. Explore other funding models that may better
support SWATs. This may be through a down-
weighted recruitment incentive for SWATs through
the CRN, or using the PROMETHEUS model of
providing a set amount to trial teams for
undertaking a SWAT, or using the new HTA
funding stream.
4. Review existing internet access in hospitals to
determine whether improved access can be enabled
to allow interventions such as multimedia websites
about trials or healthcare treatments to be accessed
more easily.
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